Beyond the trial period
Most conversations about peripheral nerve stimulation focus on the trial phase — the initial 7 to 10 days that determine whether a patient proceeds to a longer-term implant. But what happens beyond that? What do patients experience at 6 months, 12 months, and further out?
For implantable systems, the best public trial data now include two-year follow-up in defined cohorts. In the COMFORT randomized study of implantable PNS for chronic peripheral neuropathic pain, a 2026 outcomes summary reported sustained improvements at 24 months in participants who completed follow-up — not a brief effect that automatically disappears after a few months. Individual results still vary. Source: Practical Neurology, https://practicalneurology.com/news/implantable-peripheral-nerve-stimulation-shows-durable-pain-relief-at-24-months/2485516/
What the COMFORT trial reported at 24 months
According to the Practical Neurology summary of Engle et al. (2026) in Chronic Pain Management, key 24-month findings in the COMFORT analysis included: 85% of participants in the reported subset (n=39) achieved at least a 50% reduction in pain; mean pain scores improved by 67% from baseline (from 7.5 ± 1.2 to 2.4 ± 1.7); responder rates by treated region were also reported (including knee and other areas), with smaller anatomical subgroup sizes than the full cohort. Secondary outcomes — disability (ODI), depression (BDI), and quality of life (EQ-5D-5L) — improved significantly in that summary. Primary publication: https://doi.org/10.29011/2576-957X.100079
Longer-term, joint-specific evidence for every indication is still building; the honest read is that published data strongly support durability through two years in this studied implanted-PNS population, while your physician interprets how that applies to you.
Medication goals versus what trials report
Many patients hope to reduce pain medication as nerve-targeted therapy works. The COMFORT 24-month summary emphasized pain, function, mood, and quality-of-life measures rather than a single headline statistic on analgesic taper — so this library article does not quote a medication-reduction percentage from that source.
If lowering medication is a goal, it should be planned with your prescribing clinician; tapering is never something to do on your own based on marketing copy.
Why durability differs from injections
Corticosteroid and hyaluronic acid injections work by addressing the local joint environment. Their effects are inherently time-limited — the anti-inflammatory or lubricating benefit diminishes as the injected substance is metabolized. Repeated injections become less effective over time and carry cumulative risks.
Implantable PNS operates on a different mechanism: modulating nerve signaling for ongoing therapy when effective. That is why its durability profile is fundamentally different from injection cycles for patients who need something more lasting — again, with the caveat that not everyone responds the same.
What sustained relief means for daily life
For patients with chronic joint pain, even a partial reduction in daily pain can improve sleep, mood, and activity. Trial summaries such as COMFORT explicitly reported gains in disability, depression scores, and quality of life at 24 months alongside pain (see sources above).
Long-term relief isn't only a number on a pain scale — it's a return to activities chronic pain had restricted. Those outcomes are what good candidacy conversations focus on, together with realistic expectations.